Extracellular-vesicle
upin mouse cells1
Norepinephrine increases extracellular-vesicle in mouse cells.
“NE-induced activation of the β1-adrenergic receptor signaling pathway facilitated the release of exosomes and miR-125 from chondrocytes”
Cellsin chondrocytescartilage
Journal of advanced research28 Mar 2024
AMPK signalling
mixedin mouse cells1
Norepinephrine is associated with AMPK signalling in mouse cells.
“In mouse primary cells, we find that norepinephrine signaling regulates AMPK through a similar mechanism.”
Cellsthrough a Gq-PLCβ-CaMKK-dependent mechanism
Nature aging15 Mar 2021
Immune response
mixedin reviews1
Norepinephrine is associated with immune response.
“have found changes in immune responsiveness following pharmacological manipulation of noradrenergic sympathetic or peptidergic nerves”
Review
Innervation of lymphoid organs and implications in development, aging, and autoimmunity
International journal of immunopharmacology1 Apr 1992
13 Jul 1950Hypotension, blood pressure
FDA Norepinephrine Bitartrate IN 0.9% Sodium Chloride, Norepinephrine Bitartrate IN 5% Dextrose
15 Jan 2021Hypotension, blood pressure
FDA Norepinephrine Bitartrate IN 0.9% Sodium Chloride
15 Sep 2022
FDA Norepinephrine Bitartrate IN 0.9% Sodium Chloride
6 Oct 2022Hypotension, blood pressure
Phase 4Completed4 trials
Phase 3Completed1 trial
Phase 4Active, not recruiting1 trial
Phase 4Completed1 trial
Phase 4Completed4 trials
Phase 4Active, not recruiting1 trial
Phase 4Completed1 trial
Phase 3Terminated1 trial
Phase 4Completed1 trial
Phase 3Recruiting1 trial
Phase 3Terminated1 trial
Phase 3Terminated1 trial
Phase 4Completed12 trials
Phase 3Status unknown2 trials
Phase 4Active, not recruiting1 trial
Phase 4Completed1 trial
Phase 4Completed1 trial
Phase 3Completed1 trial
Phase 4Recruiting2 trials
Phase 3Recruiting1 trial
Phase 4Status unknown4 trials
Phase 4Completed1 trial
Phase 4Completed2 trials
Phase 3Completed1 trial
Phase 3Completed2 trials
Phase 2/3Completed1 trial
Phase 2/3Suspended1 trial
Phase 2/3Suspended1 trial
Phase 2Results posted1 trial
Phase 2/3Completed1 trial
Phase 1Completed1 trial
Early phase 1Recruiting1 trial
Phase 1Recruiting1 trial
Phase 1Active, not recruiting1 trial
Chronic obstructive pulmonary disease
Phase 1Recruiting1 trial
Early phase 1Terminated1 trial
Phase 1Terminated1 trial
Phase 1Completed1 trial
Early phase 1Completed1 trial
Phase 1Terminated2 trials
Cesarean Section Complications
Phase 4Completed9 trials
Diabetes Insipidus
Phase 4Completed3 trials
Spinal Anesthesia
Phase 4Completed3 trials
Respiratory distress syndrome
Phase 4Status unknown2 trials
Spinal Anesthetic Toxicity
Phase 4Completed2 trials
Aging
Early phase 1Recruiting1 trial
Pre-induction Norepinephrine in Septic Patients Undergoing Surgery
Not yet recruiting
NCT00841633TerminatedBrain ischemia
Our RCT recently started. The RCT is similar to the feasibility trial, so it was terminated to avoid 2 trials running simultaniously.
NCT02428062SuspendedCognitive dysfunction
Pending Pilot study results evaluation
NCT01263366TerminatedRadiodermatitis
Enrollment issues
NCT01367990TerminatedRadiodermatitis
Study site has terminated the study due to the complexity of the study
NCT04218773TerminatedIschemic stroke
The study was terminated prematurely due to lack of continued funding.
Company2 trialsPhase 113 people
Company1 trialPhase 112 people
8 trialsPhase 41,045 people
Second Affiliated Hospital, Zhejiang University, School of Medicine
1 trialPhase 41,000 people
1 trialPhase 41,000 people
University Hospital, Clermont-Ferrand
1 trialPhase 4300 people
1 trialPhase 4255 people
1 trialPhase 4200 people
Agence Nationale de la Recherche€644.7k
In a fly experiment, ten days of restricted feeding reduced stored fat compared with unrestricted feeding, and the loss persisted when unrestricted feeding resumed.In a fly experiment, ten days of restricted feeding reduced stored fat compared with unrestricted feeding, and the loss persisted when unrestricted feeding resumed.
In cognitively unimpaired older adults, intermediate amyloid burden showed lower dopamine-transporter deviation scores than amyloid-positive status, with an adjusted…In cognitively unimpaired older adults, intermediate amyloid burden showed lower dopamine-transporter deviation scores than amyloid-positive status, with an adjusted difference of −0.582.